Research on the Role of SLC1A5 in the Development of Esophageal Cancer
Research on the Role of the Amino Acid Transporter SLC1A5 in the Development of Esophageal Cancer
1 other identifier
observational
100
1 country
2
Brief Summary
To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2015
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2015
CompletedFirst Submitted
Initial submission to the registry
December 6, 2015
CompletedFirst Posted
Study publicly available on registry
December 17, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2018
CompletedAugust 12, 2016
August 1, 2016
2.6 years
December 6, 2015
August 11, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
optical density (ODs) of each slice by immunohistochemistry assay
For immunohistochemistry assay： Briefly, the samples will be cut into slices, which will be stained with standard steps. Finally, three high power fields will be randomly selected from each slice and the average optical density (OD) will be measured in each field.
within one year (plus or minus 1 month) after surgery
Secondary Outcomes (1)
SLC1A5 expression detected by WesternBlot
within one year (plus or minus 1 month) after surgery
Study Arms (2)
cancer tissues
SLC1A5 expression of esophageal cancer tissues from patients
paired adjacent tissues
SLC1A5 expression of paired adjacent esophageal tissues from patients
Interventions
To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
Eligibility Criteria
Patients with histologically proven esophageal cancer
You may qualify if:
- Patients with histologically proven esophageal cancer;
- Age ≥18 years;
- All patients must sign consent forms voluntarily;
You may not qualify if:
- Inability to obtain histologic proof of malignancy.
- Age \<18 years;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Liuzhou Maternity and Child Healthcare Hospital
Liuchow, Guangxi, 545000, China
The Fourth Affiliated Hospital of Guangxi Medical University
Liuchow, Guangxi, 545000, China
Biospecimen
Tissue specimens of esophageal cancer patients will be collected and stored in liquid nitrogen after operations
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Xiangcheng Wei
Guangxi Medical University Institutional Review Board
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 6, 2015
First Posted
December 17, 2015
Study Start
December 1, 2015
Primary Completion
July 1, 2018
Study Completion
August 1, 2018
Last Updated
August 12, 2016
Record last verified: 2016-08